Propoxycaine

CHEMBL1195 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
294.4 g/mol
LogP
3.1
Phase
4

Propoxycaine is an ester-type local anesthetic structurally related to procaine that blocks voltage-gated sodium channels in peripheral nerve membranes, preventing the generation and propagation of nerve impulses. It was used primarily in dentistry as an injectable local anesthetic, often in combination with procaine, for infiltration and nerve block anesthesia.

น้ำหนักโมเลกุล

294.3900 g/mol

LogP

3.10

TPSA

64.80 Ų

Lipinski RO5

ผ่าน

กลไกการออกฤทธิ์

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC

InChI

InChI=1S/C16H26N2O3/c1-4-10-20-15-12-13(17)7-8-14(15)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3

Molecular Formula

C16H26N2O3

HBD / HBA

1 / 5

พันธะที่หมุนได้

10

อะตอมหนัก

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Propoxycaine is an ester-type local anesthetic structurally related to procaine that blocks voltage-gated sodium channels in peripheral nerve membranes, preventing the generation and propagation of nerve impulses. It was used primarily in dentistry as an injectable local anesthetic, often in combination with procaine, for infiltration and nerve block anesthesia.

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Yes, Propoxycaine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1195. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6843. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.